Latest Trastuzumab Stories
DUBLIN, May 26, 2015 /PRNewswire/ -- Research and Markets(http://www.researchandmarkets.com/research/8nqqdw/global_breast)
CINCINNATI, May 26, 2015 /PRNewswire-USNewswire/ -- Maxing out the inherently stressed nature of treatment-resistant breast cancer cells thwarts their adaptive ability to evolve genetic workarounds
NEW YORK, May 14, 2015 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Puma Biotechnology, Inc.
Clinical data from a Phase 1 investigator-sponsored study to be presented for MM-398 in high-grade glioma CAMBRIDGE, Mass., May 14, 2015 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc.
Median progression-free survival of 7.6 months reported for overall study population whose disease has progressed on a median of 4 prior therapies CAMBRIDGE, Mass., April 20, 2015 /PRNewswire/
MADRID, April 14, 2015 /PRNewswire/ -- - Combination of the anticancer drug PM1183 with PARP inhibitors and doxorubicin results in a synergistic
RnRMarketResearch.com adds HER-2 Positive Breast Cancer Market in the US 2015-2019 and Global HER-2 Positive Breast Cancer Market 2015-2019 industry research reports in its store. DALLAS, March
WOONSOCKET, R.I., March 12, 2015 /PRNewswire/ -- MultiCell Immunotherapeutics, Inc. (MCIT), a majority owned subsidiary of MultiCell Technologies, Inc.
TAMPA, Fla., March 12, 2015 /PRNewswire/ -- Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc.
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.